Literature DB >> 12064375

The influence of cardiac output distribution on the tissue/plasma drug concentration ratio.

Pietro Fagiolino1.   

Abstract

In pharmacokinetics, it is currently assumed that blood and interstitial spaces belong to the central compartment, when the solute is quickly equilibrated between both fluids. Taking into account that the same extracellular fluid dissolves the drug either in the plasma or in the interstitium, both drug concentrations (intra and intravascular) should be identical. However, this equality may not exist when there is a dissimilar distribution of blood flow among the organs. A closed, two-zone, three-compartment model was mathematically investigated. Compartment 1 was intravascular, and compartments 2 and 3 were extravascular. The fluid within the compartment 1 was supposed to be pushed by a pump, and to be distributed towards two different zones. One of these zones was in contact with the compartment 2, and the other with compartment 3. The drug could be exchanged between the compartments 1 and 2 or 1 and 3, by mean of first-order kinetics (k12, k21, k13, k31). It was assumed a very fast flow that assured instantaneous homogeinity of drug concentration in compartment 1. Pressure was kept constant, so an increase in the pump output distribution towards one zone is compensated by a decrease towards the other zone. At time infinite the drug concentration (C) ratio between compartments yielded: C2/C1 = k12.sigma.V1/(k21.V2) and C3/C1 = k13.(1-sigma).V1/(k31.V3), being sigma: the pump output fraction served to the zone where compartment 2 was located, and Vi: the volumes of compartments. So, at the equilibrium the concentrations are not necessarily identical between the extravascular and intravascular sites. In conclusion, as the cardiac output distribution changes due to circadian rythms and cardiovascular active drug administration, current therapeutic drug monitoring and bioequivalence studies using plasma as biologic fluid would be controversial issues.

Mesh:

Substances:

Year:  2002        PMID: 12064375     DOI: 10.1007/BF03190420

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  2 in total

Review 1.  Is there a need for more precise definitions of bioavailability? Conclusions of a consensus workshop, Munich, September 9, 1989; under the patronage of the F.I.P.

Authors: 
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Chronopharmacological aspects of PK/PD modelling.

Authors:  B Lemmer
Journal:  Int J Clin Pharmacol Ther       Date:  1997-10       Impact factor: 1.366

  2 in total
  4 in total

1.  Multiplicative dependence of the first order rate constant and its impact on clinical pharmacokinetics and bioequivalence.

Authors:  Pietro Fagiolino
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Jan-Mar       Impact factor: 2.441

Review 2.  The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/pharmacodynamic relationships.

Authors:  Pietro Fagiolino; Rosa Eiraldi; Marta Vázquez
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  In vitro approach to study the influence of the cardiac output distribution on drug concentration.

Authors:  P Fagiolino; F Wilson; E Samaniego; M Vázquez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Apr-Jun       Impact factor: 2.441

4.  Current PBPK Models: Are They Predicting Tissue Drug Concentration Correctly?

Authors:  Manuel Ibarra; Marta Vázquez; Pietro Fagiolino
Journal:  Drugs R D       Date:  2020-10-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.